HOME >> MEDICINE >> NEWS
New data supports CellCept's position as a world leader in solid organ transplantation

19 May 2004, Basel, Switzerland New data presented this week in over 70 abstracts at the American Transplant Congress in Boston, USA strengthen even further the body of evidence that CellCept (mycophenolate mofetil, MMF) is the most reliable, efficacious, low toxic immunosuppressant for adult and paediatric kidney, heart and liver transplant patients.

The collective data presented at the ATC, in which more than 61,000 transplant patients where studied, demonstrate that CellCept-based therapies have unique benefits for solid organ transplant patients such as:

  • Proven patient survival benefits
  • Lowest toxicity profile
  • The greatest reduction in acute and chronic rejection

"In order for us to choose the best immunosuppressant regimen for our patients, we need to consider acute rejection, long term graft function, minimal toxic side-effects and, most importantly, graft and patient survival", said Prof Meier- Kriesche, University of Florida, Gainsville, FL, USA. "Long term data with meaningful patient numbers, data and experience from our peers, allows us to decide on the best low toxic combination for better outcomes and patient survival. CellCept's 10 years of clinical experience, in addition to early clinical trials, provides us that real world data", he added.

Highlights from the wealth of data presented at ATC
in adult liver transplant patients
Lake R, Chu AH, Steffen BJ, et al. Efficacy of triple therapy with mycophenolate mofetil (MMF), tacrolimus (TACRO) and corticosteroids (CS) compared to TACRO and CS immunosuppression in liver transplantation: an analysis of the US liver transplant experience. Abstract 395, ATC 2004. CellCept reduced acute rejection rates in a study of 11,670 liver transplant patients, when added to a tacrolimus based immunosuppressant regimen. Graft and patient survival significantly improved (p<0.0001), whilst the risk for infect
'"/>

Contact: Cendrine Banerjee-Quetel
cendrine.banerjee-quetel@ketchum.com
44-207-611-3656
Ketchum
19-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Emergency department study supports giving dehydrated children fluids by mouth
2. Review supports link between HRT and stroke
3. Chamomile tea: New evidence supports health benefits
4. Social supports lessen effects of maltreatment on children vulnerable to depression
5. Study supports the use of mechanical assistance
6. Study supports aggressive treatment of heart patients with cholesterol-lowering medication
7. NCI grant supports Jefferson trial to study test for colorectal cancer recurrence
8. Study supports new theory for nicotines protective effect against neurodegenerative disorders
9. New study supports use of PET scans in early diagnosis of Alzheimers disease
10. Contraception study supports convenience, simplicity
11. International grant supports study related to preventing organ rejection

Post Your Comments:
(Date:3/4/2015)... 2015 TROY Healthcare Solutions will be ... the ultimate level of security for prescriptions, in Houston, ... Plaza Medical Center located at 6633 Travis Street from ... 7 AM, TROY Healthcare Solutions will host a continental ... offer brief presentations each hour to introduce attendees to ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... creative, breakthrough marketing campaign called 'We Love Smokers' from ... cravings for tobacco. , "It’s important to establish ... be true to it. Our idea, 'We Love Smokers' ... leadership point of view. We created a bold tone ...
(Date:3/4/2015)... 2015 Starting February 2015, Dr. Joseph ... procedures at their new location in Surrey. , In ... and Dr. Gabriel Chu also provide comprehensive ophthalmology services, ... named Fraser Valley Cataract and Laser (FVCL). This state ... College of Physicians and Surgeons of British Columbia. Fraser ...
(Date:3/4/2015)... 2015 " Optrix by Body Glove ... monthly Tech Report, which takes a look at the ... consumers. Scott Steinberg, a special reporter for NewsWatch and ... with viewers how they have an ultra-rugged, waterproof case ... is a major player at the Consumer Electronics Show ...
(Date:3/4/2015)... 2015 The New Mel Brooks Musical ... will be performed by the award-winning Drama Department of ... March 6-22, 2015, on Fridays, Saturdays and Sundays. Performances ... School (27118 Silver Spur Road, Rolling Hills Estates, ... program or may be purchased on-line at https://sites.google.com/site/penhidrama ...
Breaking Medicine News(10 mins):Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:King LASIK relocates to Surrey, British Columbia 2Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2
(Date:3/4/2015)... 4, 2015  Bayer HealthCare today announced that ... accepted the company,s Biologics License Application (BLA) for ... is seeking FDA approval of the investigational compound, ... hemophilia A in children and adults. ... therapies to hemophilia A patients who need them," ...
(Date:3/4/2015)... Colo. , March 4, 2015  Heska Corporation ... What:Heska Corporation Invites You to Join Its Fourth Quarter ... WebWhen:Thursday, March 5, 2015 @ 9:00 a.m. (MST) / ... and Year End 2014 Earnings Call link on the ... Simply log on to the web at the address ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4f69k2/negative_pressure ) ... Pressure Wound Therapy Market (Conventional and Single Use ... Growth, Trends and Forecast 2014 - 2020" ... The global negative pressure wound therapy market is ... product types the NPWT market is segmented into ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2
Cached News: